Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

ByEthan Sokol,Smruthy Sivakumar,Dexter X. Jin,Hanna Tukachinsky,Karthikeyan Murugesan,Dean Pavlick,Jeffrey S. Ross, MD,Garrett M. Frampton,Geoffrey R. Oxnard, MD,Priti S. Hegde

April 18th 2022

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

ByGeoffrey R. Oxnard, MD,Vincent A. Miller, MD

April 30th 2010

Tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR), such as erlotinib (Tarceva) and gefitinib (Iressa), have shown remarkable activity in a portion of patients with non–small-cell lung cancer (NSCLC).

Latest Updated Articles

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC
April 30th 2010

Geoffrey R. Oxnard, MD

Articles by Geoffrey R. Oxnard, MD

42 Tissue and Liquid Biopsy–Based Comprehensive Genomic Profiling Reveal Mechanisms of Therapy Resistance and Rare Targetable Alterations in Breast Cancer

Use of Erlotinib or Gefitinib as Initial Therapy in Advanced NSCLC

Latest Updated Articles

Trending on CancerNetwork

The Rise of Early-Onset Cancers: Investigating Breast and CRC Occurrences

Endometrial Cancer Treatment Options: What are the Experts Using?

FDA Grants Priority Review to Lirafugratinib in FGFR2+ Cholangiocarcinoma

Global Health Award Will Expand Prostate Cancer Care to Nigeria

LITESPARK-011 Regimen: Potentially A New SOC in PD-1 Pretreated ccRCC?